No Data
Top Premarket Decliners
Why BloomZ Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
Buy Rating on Mersana Therapeutics: Anticipated Upside From XMT-1660 Development and Market Valuation Disconnect
LifeSci Capital Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Maintains Target Price $8
Truist Financial Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Announces Target Price $9
Mersana Therapeutics Is Maintained at Buy by Citigroup